You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation II1 Apr 2017MP10-09 SUPPRESSED RECURRENT BLADDER CANCER AFTER ANDROGEN SUPPRESSION WITH ANDROGEN-DEPRIVATION THERAPY OR 5?-REDUCTASE INHIBITOR Masaki Shiota, Keijiro Kiyoshima, Akira Yokomizo, Ario Takeuchi, Eiji Kashiwagi, Ryosuke Takahashi, Junichi Inokuchi, Katsunori Tatsugami, and Masatoshi Eto Masaki ShiotaMasaki Shiota More articles by this author , Keijiro KiyoshimaKeijiro Kiyoshima More articles by this author , Akira YokomizoAkira Yokomizo More articles by this author , Ario TakeuchiArio Takeuchi More articles by this author , Eiji KashiwagiEiji Kashiwagi More articles by this author , Ryosuke TakahashiRyosuke Takahashi More articles by this author , Junichi InokuchiJunichi Inokuchi More articles by this author , Katsunori TatsugamiKatsunori Tatsugami More articles by this author , and Masatoshi EtoMasatoshi Eto More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.337AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES It has been suggested that androgen-suppression therapy (AST) may inhibit the occurrence of primary bladder cancer as well as intravesical recurrence of bladder cancer. This study aimed to reveal whether intravesical recurrence is affected by an inhibition of androgen signaling among men with non-muscle invasive bladder cancer. METHODS This study examined the intravesical recurrent rate among men treated with or without AST by androgen-deprivation therapy for prostate cancer or 5a-reductase inhibitor dutasteride for benign prostatic hyperplasia. RESULTS This study included 228 men with AST (n = 32) or without AST (n = 196). During the median follow-up period of 3.6 or 3.0 years, intravesical recurrence occurred in four (12.5%) or 59 (30.1%) of men with or without AST, respectively. On multivariate analysis, multiple tumor (hazard ration, HR = 1.82, p = 0.027), large tumor (HR = 2.13, p = 0.043) and ever smoking (HR = 2.45, p = 0.020) as well as the presence of AST (HR = 0.36, p = 0.024) were independent risk factors for intravesical recurrence (Fig. A). Notably, tumor progression to muscle-invasive bladder cancer occurred in six (3.1%) men without AST, while no case progressed to muscle-invasive bladder cancer in men with AST. CONCLUSIONS Our study suggested the possibility of AST for prophylactic use of intravesical recurrence of bladder cancer. Further explorations on the prophylactic effect of AST on bladder cancer pathogenesis are warranted. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e111 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Masaki Shiota More articles by this author Keijiro Kiyoshima More articles by this author Akira Yokomizo More articles by this author Ario Takeuchi More articles by this author Eiji Kashiwagi More articles by this author Ryosuke Takahashi More articles by this author Junichi Inokuchi More articles by this author Katsunori Tatsugami More articles by this author Masatoshi Eto More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...